SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is a top trending stock following its earnings report, which, despite beating estimates, has been overshadowed by concerns regarding the Warner Bros Discovery acquisition. The community is sharply divided, with bulls viewing the current dip as an oversold opportunity for long-term content expansion, while bears cite the deal's cost, debt implications, and paused share buybacks as reasons for further downside. This strategic move and its perceived impact on future margins are driving intense discussion and significant price action.

Brand Engagement Network, Inc. engages in the provision of conversational artificial intelligence assistants with the purpose of transforming engagement and analytics for businesses through security-focused, multimodal communication and human-like artificial intelligence assistants. The firm is also involved in delivering highly personalized, multi-modal artificial intelligence engagement with a focus on industries where there is a massive workforce gap and an opportunity to transform how consumers engage with networks, providers, and brands. The company is founded on March 14, 2024 and is headquartered in Jackson, WY.

Brand Engagement Network Inc

Brand Engagement Network ($BNAI) is experiencing significant market attention following news of a strategic AI licensing partnership in Africa, including a pilot program with Nelson Mandela University. This development, combined with discussions around a reportedly thin float and high short interest, is driving substantial pre-market volatility and community speculation about a potential short squeeze. Traders are actively monitoring for sustained momentum, positioning BNAI as a key focus within the AI sector narrative.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Alpha Tau Medical (DRTS) is trending with immense community excitement, primarily driven by the high anticipation of potential PMDA Japan approval for its Alpha DaRT therapy, following compelling pancreatic cancer data. Investors are increasingly bullish, viewing recent strong clinical updates and growing institutional interest as key catalysts for this innovative oncology technology, which many believe is poised for significant recognition.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

SPDR Gold Shares ETF (GLD) is experiencing a parabolic rally to new record highs, driven by escalating global trade tensions and broad geopolitical uncertainty. The community is actively discussing gold's role as a safe haven amidst concerns over sovereign debt, potential currency debasement, and central bank diversification, fueling significant short-covering and strong bullish momentum.

ProShares Trust - ProShares UltraShort Bloomberg Natural Gas -2x Shares

ProShares UltraShort Bloomberg Natural Gas

KOLD is experiencing significant volatility and declines as natural gas futures surge dramatically, driven by widespread "Arctic Blast" weather forecasts across the US. This rapid price action is causing extreme pressure for many traders, leading to discussions of a "widowmaker" market as some cautiously "buy the dip" on KOLD while others are caught in the squeeze.

PAVmed, Inc. is a multi-product life sciences company, which engages in the innovation, development, acquisition, and commercialization of products that target unmet medical needs with large addressable market opportunities. Its products include Lucid Diagnostics and Veris Health. The company was founded by Lishan Aklog and Brian J. deGuzman on June 26, 2014 and is headquartered in New York, NY.

PAVmed Inc

PAVmed is currently a top trending stock after its subsidiary, Lucid Diagnostics, announced a major contract with the U.S. Department of Veterans Affairs for its EsoGuard esophageal DNA test. This significant development has ignited investor excitement, with many discussing the potential for substantial price movement given the company's low float, even as some longer-term holders express caution regarding historical performance.

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPY is trending due to immediate market uncertainty surrounding an anticipated speech by Donald Trump at Davos, sparking community debate over potential tariffs and geopolitical tensions, particularly regarding Greenland. Sentiment is split, with some traders concerned about rising Japanese bond yields and broader market weakness, while others expect a rebound, highlighting underlying economic resilience and a potential rotation into small-cap and value stocks.

Memecoin on Cronos launched by the Cro Crow community

crow with knife

Crow With Knife ($CAW) is currently a trending multi-chain meme coin, garnering significant attention as its community emphasizes its deflationary mechanics and organic cult-like growth across Solana, Cronos, and Base. Enthusiasts are actively discussing its potential to bring substantial volume to various chains and are anticipating further developments like staking opportunities, positioning it as a formidable player in the meme coin sector.

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals is trending due to overwhelmingly positive Phase 1 clinical trial results for its atopic dermatitis drug, soquelitinib, demonstrating strong efficacy and a favorable safety profile even in treatment-resistant patients. This promising early data has ignited bullish sentiment about its blockbuster potential and possible short squeeze, despite community concerns surrounding a recently announced public offering to fund future trials.

Hycroft Mining Holding Corp. engages in the exploration, mining, and development of gold and silver properties. The company was founded on August 28, 2017 and is headquartered in Winnemucca, NV.

Hycroft Mining Holding Corporation - Ordinary Shares - Class A

Hycroft Mining Holding Corp

Hycroft Mining is seeing a significant surge in conversation, driven by recent reports of high-grade silver and gold drill results and continued accumulation by mining billionaire Eric Sprott. The community is intensely divided, with many anticipating a substantial short squeeze and linking its prospects to a booming precious metals market, while others caution about potential dilution and the company's lack of current production.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Lucid Capital raised the firm's price target on Main Street to $65 from $60.</li><li>Main Street said its preliminary estimate of fourth quarter 2025 net investment income is $1.01 to $1.05 per share.</li><li>It sees its net asset value rise between 1.5% to 1.8% on a sequential basis.</li></ul><p>Main Street Shares rose on Thursday after it reported preliminary estimates for fourth quarter (Q4) that prompted an analyst to raise the price target on the company’s stock.&nbsp;</p><p>“Our preliminary operating results highlight that our fourth quarter performance resulted in another quarter of strong operating results, including favorable distributable net investment income per share and a new record for net asset value per share for the fourteenth consecutive quarter,” Main Street's CEO Dwayne L. Hyzak said.&nbsp;</p><p>“We also produced extremely strong fourth quarter investment activity in our unique lower middle market investment strategy, resulting in an annual record for gross investments of approximately $700 million in 2025,” he added.</p><h2 class="st-heading-2">Q4 Prelim estimates</h2><p>Main Street said its preliminary estimate of fourth quarter 2025 net investment income is $1.01 to $1.05 per share. It sees Q4 net asset value (NAV) per share of $33.29-$33.37, representing a 1.5% to 1.8% rise on a sequential basis.&nbsp;</p><p>The estimated NAV per share increase is primarily due to the net fair value increase of the investment portfolio, the company said. The rally in the equities market at the end of last year has helped firms who invest client’s money in the capital market as they saw the value of assets of their clients go up as a result of the market rally.&nbsp;</p><p>The company is expected to post its full results in late February, the company said.&nbsp;</p><h2 class="st-heading-2">Analyst Action</h2><p>Lucid Capital raised the firm's price target on Main Street to $65 from $60 and kept a ‘Neutral’ rating on the shares, as per TheFly.&nbsp;</p><p>The company's preliminary Q4 guidance included "robust" net interest income, investment performance and net asset value growth both above Street estimates, the note said. However, the firm believes Main Street's valuation largely reflects its earnings power and growth potential.&nbsp;</p><h2 class="st-heading-2">How Did Stocktwits Users React?</h2><p>Retail sentiment around MAIN trended in ‘bearish’ territory amid ‘high’ message volume.</p><p>Shares of Main Street Capital have risen almost 10% over the past year.&nbsp;<br>&nbsp;</p>

Stocks, shares background - stock photo (representative image courtesy of Sean Gladwell via Getty Images)

Main Street Shares Rise As Strong Prelim Estimates For Q4 Impress Analyst

An analyst at Lucid Capital said that Main Capital’s preliminary Q4 guidance included "robust" net interest income, investment performance and net asset value growth both above Street estimates. 

Equity

An analyst at Lucid Capital said that Main Capital’s preliminary Q4 guidance included "robust" net interest income, investment performance and net asset value growth both above Street estimates. 


From SpaceX to xAI: How ETFs Are Packaging Private Assets

ETFs are opening doors to private markets: here's what investors need to know

ProShares Trust - ProShares Global Listed Private Equity ETF

Up 10% or more

0% to up 9%

Down 1% to 9%

Down 10% or more

The S&P 500 enters 2026 after a strong run. What kind of return do you expect this year?

How will the S&amp;P 500 perform in 2026?

PEX
ProShares Global Listed Private Equity ETF

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest PEX News

PEXProShares Global Listed Private Equity ETF